These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24922636)

  • 1. Immunohistochemical comparison of biomarker expression in biopsy and surgical specimens of non-small cell lung cancer.
    Okimoto T; Tsubata Y; Sutani A; Fuchita H; Koba N; Hotta T; Hamaguchi M; Miura K; Hamaguchi S; Ohe M; Kuraki T; Harada Y; Maruyama R; Miyamoto N; Kishimoto K; Isobe T
    Anticancer Res; 2014 Jun; 34(6):2755-61. PubMed ID: 24922636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
    Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
    Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
    Gomez-Roca C; Raynaud CM; Penault-Llorca F; Mercier O; Commo F; Morat L; Sabatier L; Dartevelle P; Taranchon E; Besse B; Validire P; Italiano A; Soria JC
    J Thorac Oncol; 2009 Oct; 4(10):1212-20. PubMed ID: 19687761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
    Chiappori AA; Zheng Z; Chen T; Rawal B; Schell MJ; Mullaney BP; Bepler G
    J Thorac Oncol; 2010 Apr; 5(4):484-90. PubMed ID: 20107425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
    Zhang Y; Yang H; Qiu Y; Deng Q; Liu J; Zhao M; He P; Mo M; Zou X; He J
    Med Oncol; 2014 Mar; 31(3):803. PubMed ID: 24452282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
    Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
    Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
    Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR
    Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
    Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
    J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.
    Maus MK; Mack PC; Astrow SH; Stephens CL; Zeger GD; Grimminger PP; Hsiang JH; Huang E; Li T; Lara PN; Danenberg KD; Gandara DR
    J Thorac Oncol; 2013 May; 8(5):582-6. PubMed ID: 23470290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
    Zhang Q; Zhu X; Zhang L; Sun S; Huang J; Lin Y
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):839-46. PubMed ID: 25119181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
    Zheng Z; Li X; Schell MJ; Chen T; Boulware D; Robinson L; Sommers E; Bepler G
    Cancer; 2008 Jun; 112(12):2765-73. PubMed ID: 18442042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance.
    Yeo CD; Park GS; Kang N; Choi SY; Kim HY; Lee DS; Kim YS; Kim YK; Park JG; Sung SW; Lee KY; Park MS; Yim HW; Kim SJ; Lee JH
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1365-70. PubMed ID: 25968616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.